ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
Portfolio Pulse from
ViiV Healthcare, majority owned by GSK with Pfizer and Shionogi as shareholders, announced new data showing zero HIV cases with Apretude, a long-acting injectable for HIV prevention. Real-world data for Cabenuva also showed effectiveness over three years.
March 12, 2025 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer, a shareholder in ViiV Healthcare, benefits from positive data on Apretude and Cabenuva, enhancing its portfolio in HIV prevention and treatment.
Pfizer, as a shareholder in ViiV Healthcare, stands to benefit from the positive data on Apretude and Cabenuva. This strengthens its position in the HIV treatment and prevention market, potentially boosting investor confidence and stock performance.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50